Literature DB >> 21122540

The pattern and outcome of acute severe colitis.

Lotte C Dinesen1, Alissa J Walsh, Marijana Nedeljkovic Protic, Graham Heap, Fraser Cummings, Bryan F Warren, Bruce George, Neil J M Mortensen, Simon P L Travis.   

Abstract

BACKGROUND: The prognosis of acute severe ulcerative colitis (ASC) influences therapeutic decisions, but data on prevalence or long-term outcome are few.
METHODS: A systematic review of all patients with UC diagnosed in Oxford was performed to assess the prevalence of ASC defined by Truelove and Witts' (TW) criteria and determine whether outcome is related to disease activity on admission, likelihood of recurrence and long-term prognosis.
RESULTS: 750 patients (median follow up 12.7 yr, range 0-648 mo) met inclusion criteria out of a total cohort of 1853 patients. 24.8% (186/750) had at least one admission for ASC (294 admissions in 186 patients). Overall, 12% (93/750) had a colectomy, compared to 39.8% (74/186) of patients with one or more episodes of ASC (p<0.0001) and 3.4% (19/564) in those with no admission. The colectomy rate on first admission (37/186, 19.9%) was lower than on the second or subsequent admissions (OR 2.35, 95% CI 1.33-4.14, p=0.003), being 29.0%, 36.6%, 38.2% after two, three, or subsequent episodes respectively. It was 8.5% (11/129) if patients had one TW criterion in addition to ≥6 bloody bowel motions/day, compared to 31% (29/94) if two additional criteria were present and 48% (34/71) if three or more additional criteria were present (p=1.4 × 10⁻⁵; OR 4.35, 95% CI 2.20-8.56 one criterion vs two or more).
CONCLUSIONS: A quarter of all patients with ulcerative colitis experience at least one episode of ASC; 20% come to colectomy on first admission, but 40% after two admissions. The likelihood of colectomy is related to biological severity on admission.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122540     DOI: 10.1016/j.crohns.2010.02.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  76 in total

1.  Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.

Authors:  Amar Vedamurthy; Louise Xu; Jay Luther; Francis Colizzo; John J Garber; Hamed Khalili; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2018-06-27       Impact factor: 3.199

Review 2.  Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Authors:  Kaitlin G Whaley; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

4.  Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease.

Authors:  Saurabh Kedia; Saransh Jain; Sandeep Goyal; Sawan Bopanna; Dawesh P Yadav; Vikas Sachdev; Peush Sahni; Sujoy Pal; Nihar Ranjan Dash; Govind Makharia; Simon P L Travis; Vineet Ahuja
Journal:  Dig Dis Sci       Date:  2018-06-08       Impact factor: 3.199

Review 5.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

6.  Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Authors:  Hui-Min Wu; Juan Wei; Jin Li; Kai Wang; Lei Ye; Ying Qi; Bo-Si Yuan; Yu-Lin Yang; Li Zhao; Zhao Yang; Miao-Fang Yang; Jian-Feng Gong; Fang-Yu Wang
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

7.  Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Authors:  Matthew C Choy; Dean Seah; David M Faleck; Shailja C Shah; Che-Yung Chao; Yoon-Kyo An; Graham Radford-Smith; Talat Bessissow; Marla C Dubinsky; Alexander C Ford; Leonid Churilov; Neville D Yeomans; Peter P De Cruz
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

Review 8.  MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE.

Authors:  Carlos Walter Sobrado; Lucas Faraco Sobrado
Journal:  Arq Bras Cir Dig       Date:  2016 Jul-Sep

9.  Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.

Authors:  Jeffrey A Berinstein; Calen A Steiner; Randolph E Regal; John I Allen; Jami A R Kinnucan; Ryan W Stidham; Akbar K Waljee; Shrinivas Bishu; Leslie B Aldrich; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-17       Impact factor: 11.382

10.  Outcomes for Ulcerative Colitis With Delayed Emergency Colectomy Are Worse When Controlling for Preoperative Risk Factors.

Authors:  Ira L Leeds; Margaret H Sundel; Alodia Gabre-Kidan; Bashar Safar; Brindusa Truta; Jonathan E Efron; Sandy H Fang
Journal:  Dis Colon Rectum       Date:  2019-05       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.